Determination of zafirlukast, a selective leukotriene antagonist, human plasma by normal-phase high-performance liquid chromatography with fluorescence detection

被引:21
作者
Bui, KH
Kennedy, CM
Azumaya, CT
Birmingham, BK
机构
[1] Drug Disposition and Metab. Dept., ZENECA Pharmaceuticals, Wilmington, DE 19897
[2] E.I. du Pont de Nemours and Company, DuPont Agricultural Products, Experimental Station, Wilmington
来源
JOURNAL OF CHROMATOGRAPHY B | 1997年 / 696卷 / 01期
关键词
zafirlukast;
D O I
10.1016/S0378-4347(97)00092-3
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A high-performance liquid chromatographic (HPLC) method was developed for the determination of zafirlukast, a selective peptide leukotriene receptor antagonist, in human plasma. Zafirlukast and the internal standard, ICI 198 707, were extracted from deproteinated plasma samples using large reservoir C-18 solid-phase extraction columns and analyzed by normal-phase liquid chromatography with fluorescence detection. The method had a lower limit of quantitation of 0.75 ng/ml and a linear calibration curve in the range of 0.75 to 200 ng/ml. The absolute recovery of zafirlukast was >90%, and the within-day and between-day relative standard deviations were <9%. The utility of the method in the characterization of the plasma concentration-time profiles of zafirlukast in clinical studies was demonstrated. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:131 / 136
页数:6
相关论文
共 7 条